Novobiocin analogs lacking labile glycosidic ether have been designed, synthesized and evaluated for Hsp90 inhibitory activity. Replacement of the synthetically complex noviose sugar with simple aromatic side chains produced analogs that maintain moderate cytotoxic activity against MCF7 and SkBR3 breast cancer cell-lines. Rationale for the preparation of des-noviose novobiocin analogs in addition to their synthesis and biological evaluation are presented herein
Modulation of Hsp90 C-terminal function represents a promising therapeutic approach for the treatmen...
Dissertation (Ph.D.)--University of Kansas, Medicinal Chemistry, 2007.The 90 kDa heat shock proteins...
Hsp90 is an attractive therapeutic target for the treatment of cancer. Extensive structural modific...
Novobiocin analogs lacking labile glycosidic ether have been designed, synthesized and evaluated for...
Hsp90 is a promising therapeutic target for the treatment of cancer. Novobiocin is the first Hsp90 C...
Since Hsp90 modulates all six hallmarks of cancer simultaneously, it has become an attractive target...
Development of heat shock protein 90 (Hsp90) C‐terminal inhibitors has emerged as an exciting strate...
Novobiocin, a known DNA gyrase inhibitor, binds to a nucleotide-binding site located on the Hsp90 C-...
The research described in this thesis focuses on heat shock protein 90 kDa (Hsp90), which is a molec...
This document is the Accepted Manuscript version of a Published Work that appeared in final form in ...
Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplish...
The design, synthesis and biological evaluation of conformationally constrained coumermycin A1 analo...
As C−terminal inhibitors of a 90−kDa heat shock protein (Hsp90), novobiocin and its deri...
Hsp90 C-terminal inhibitors represent a novel and alternative chemotherapeutic approach for the trea...
A series of triazole-containing novobiocin analogues has been designed, synthesized and their inhibi...
Modulation of Hsp90 C-terminal function represents a promising therapeutic approach for the treatmen...
Dissertation (Ph.D.)--University of Kansas, Medicinal Chemistry, 2007.The 90 kDa heat shock proteins...
Hsp90 is an attractive therapeutic target for the treatment of cancer. Extensive structural modific...
Novobiocin analogs lacking labile glycosidic ether have been designed, synthesized and evaluated for...
Hsp90 is a promising therapeutic target for the treatment of cancer. Novobiocin is the first Hsp90 C...
Since Hsp90 modulates all six hallmarks of cancer simultaneously, it has become an attractive target...
Development of heat shock protein 90 (Hsp90) C‐terminal inhibitors has emerged as an exciting strate...
Novobiocin, a known DNA gyrase inhibitor, binds to a nucleotide-binding site located on the Hsp90 C-...
The research described in this thesis focuses on heat shock protein 90 kDa (Hsp90), which is a molec...
This document is the Accepted Manuscript version of a Published Work that appeared in final form in ...
Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplish...
The design, synthesis and biological evaluation of conformationally constrained coumermycin A1 analo...
As C−terminal inhibitors of a 90−kDa heat shock protein (Hsp90), novobiocin and its deri...
Hsp90 C-terminal inhibitors represent a novel and alternative chemotherapeutic approach for the trea...
A series of triazole-containing novobiocin analogues has been designed, synthesized and their inhibi...
Modulation of Hsp90 C-terminal function represents a promising therapeutic approach for the treatmen...
Dissertation (Ph.D.)--University of Kansas, Medicinal Chemistry, 2007.The 90 kDa heat shock proteins...
Hsp90 is an attractive therapeutic target for the treatment of cancer. Extensive structural modific...